Get the Stockscreener App
3.23
3.86%
0.12
Recursion Pharmaceuticals Inc stock is traded at $3.23, with a volume of 24.73M.
It is up +3.86% in the last 24 hours and up +11.76% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.11
Open:
$3.18
24h Volume:
24.73M
Relative Volume:
1.58
Market Cap:
$1.71B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-2.6867
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
+2.54%
1M Performance:
+11.76%
6M Performance:
-27.25%
1Y Performance:
-36.79%
1-Day Range:
$3.11
$3.28
1-Week Range:
$3.07
$3.39
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.23 | 1.71B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals (RXRX) Proxy Filing Summary - Quartr
Recursion Pharmaceuticals (RXRX) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Recursion Pharmaceuticals (RXRX) dips more than broader market: What you should know - MSN
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals shareholders elect directors and approve proposals at annual meeting - Investing.com UK
Recursion (NASDAQ: RXRX) investors back board nominees and PwC as 2026 auditor - Stock Titan
Christopher C. Gibson sells six 40,000-share lots (RXRX) across Mar–Jun 2026 - Stock Titan
RXRX (NASDAQ) affiliate files Form 144 to sell 3,963 Class A shares - Stock Titan
RXRX (NASDAQ) proposed resale of multiple 40,000-share blocks between Mar–Jun 2026 - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Taylor Ben R - Moomoo
Recursion (NASDAQ: RXRX) CFO covers taxes with 5,396 withheld shares - Stock Titan
Recursion Pharmaceuticals (RXRX) Bank of America Global A.I. Conference 2024 Summary - Quartr
RXRX: All proposals passed, including board elections and auditor ratification, with no stockholder questions - TradingView
Recursion Pharmaceuticals Inc (RXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Recursion Pharmaceuticals Inc - TradingKey
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Institutional Confidence - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It - Benzinga
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Early Safety Data And FDA Signals Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - Sahm
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed (RXRX) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI-Driven Drug Discovery Advances - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX: AI-driven platform advances multiple clinical programs with major data readouts expected soon - TradingView
Recursion Pharmaceuticals (RXRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Here’s Why Recursion Pharmaceuticals (RXRX) is Among the Best Penny Stocks - Insider Monkey
Recursion Pharmaceuticals Stock Surges After Consecutive Losses - asatunews.co.id
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceutica - GuruFocus
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock - Investing.com UK
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade - Stock Titan
Recursion Q1 2026 slides: pipeline advances amid revenue shortfall - Investing.com
Najat Khan plans Rule 144 sale of Recursion (NASDAQ: RXRX) shares on 05/15/2026 - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway - Sahm
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Gibson files Form 144 to sell 40,000 Class A shares (RXRX) - Stock Titan
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bumpus Namandje - Moomoo
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business Updates - Insider Monkey
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):